Adoptive transfer of autologous Epstein‐Barr virus–specific cytotoxic T cells for nasopharyngeal carcinoma

• Published in: International journal of cancer Vol. 94; no. 1; pp. 73 - 80
• Main Authors: Chua, Daniel, Huang, Jie, Zheng, Bojian, Lau, See Yan, Luk, Winsie, Kwong, Dora L.W., Sham, Jonathan S.T., Moss, Denis, Yuen, Kwok Yung, Im, Stanley W.K., Ng, Mun Hon
• Format: Journal Article
• Language: English
• Published: New York John Wiley & Sons, Inc 01.10.2001; Wiley-Liss
• Subjects: adoptive immune transfer; Adoptive Transfer; Adult; Biological and medical sciences; cytotoxic T cell; Diseases of the upper aerodigestive tract; Ent and stomatology; Epstein-Barr virus; Female; Hematopoietic Stem Cells - immunology; Herpesvirus 4, Human - immunology; Humans; Male; Medical sciences; Middle Aged; nasopharyngeal carcinoma; Nasopharyngeal Neoplasms - immunology; Nasopharyngeal Neoplasms - therapy; Nasopharyngeal Neoplasms - virology; peripheral blood monocyte; Radiotherapy. Instrumental treatment. Physiotherapy. Reeducation. Rehabilitation, orthophony, crenotherapy. Diet therapy and various other treatments (general aspects); T-Lymphocytes, Cytotoxic - immunology; Tumor Cells, Cultured; Gammaherpesvirinae; Human; Carcinoma; Herpesviridae; Nasopharynx; Epstein Barr virus; Malignant tumor; Infection; Virus; Treatment; Immunotherapy; Viral disease; ENT disease; Pharynx disease; Adoptive immunization; Cytotoxic T lymphocyte
• ISSN: 0020-7136; 1097-0215
• DOI: 10.1002/ijc.1430

Tumor cells from NPC patients are regularly and latently infected with EBV. To examine whether the virus serves as target for immune intervention of the cancer, we determined levels of EBV‐specific CTLp in peripheral blood from NPC patients, long‐term survivors of the cancer and healthy subjects. CTLp levels of test subjects varied between 3– 3,000/106 PBMCs. The plasma EBV burden increased when the CTLp level fell below 150, whereas the EBV burden of PBMCs was not correlated with CTLp level. Compared with healthy carriers, CTLp levels of patients were lower and varied over a wider range, between 3–1,500/106 PBMCs. The quantitative immune deficit was probably attributed to the tumor because, first, CTLp in survivors was restored to levels similar to those in healthy carriers after the tumor had been successfully treated. Second, the CTLp level changed as disease progressed, being lower in local disease, increased in locoregional disease and decreased again when the tumor metastasized. Based on these findings, 4 patients with advanced disease were infused with 5 × 107–3 × 108 autologous EBV CTLs. The treatment was safe and unaccompanied by inflammatory or other complications, but whether it improved tumor control could not be discerned from the large tumor bulk. Nevertheless, the treatment regularly increased CTLp levels of patients, maintained it at higher levels for protracted periods and, in 3 patients, restored host surveillance of EBV replication, reducing the plasma EBV burden. Taken together, these results provided a rationale to further explore EBV as a target of immune intervention of NPC. © 2001 Wiley‐Liss, Inc.